Co-treatment with natural HMGB1 inhibitor Glycyrrhizin exerts neuroprotection and reverses Parkinson’s disease like pathology in Zebrafish

Ren, Qingyu; Jiang, Xin; Paudel, Yam Nath; Gao, Xin; Gao, Daili; Zhang, Pengyu; Sheng, Wenlong; Shang, Xueliang; Liu, Kechun; Zhang, Xiujun; Jin, Meng

doi:10.1016/j.jep.2022.115234

Cited by 18 publications

(11 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both A box and B box are composed of three α-helix structures, which can interact with deoxyribonucleic acid (DNA) nonspecifically (5). HMGB1 has two nuclear localization sequences (NLSs) located between the A box (aa [28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] and the B box and C-terminal tail (aa 179-185) (6). When immune cells respond to endogenous or exogenous stimuli such as endotoxin, interleukin, and hypoxia, HMGB1 can be actively released (7).…”

Section: Introductionmentioning

confidence: 99%

HMGB1 in nervous system diseases: A common biomarker and potential therapeutic target

et al. 2022

View full text Add to dashboard Cite

High-mobility group box-1 (HMGB1) is a nuclear protein associated with early inflammatory changes upon extracellular secretion expressed in various cells, including neurons and microglia. With the progress of research, neuroinflammation is believed to be involved in the pathogenesis of neurological diseases such as Parkinson's, epilepsy, and autism. As a key promoter of neuroinflammation, HMGB1 is thought to be involved in the pathogenesis of Parkinson's disease, stroke, traumatic brain injury, epilepsy, autism, depression, multiple sclerosis, and amyotrophic lateral sclerosis. However, in the clinic, HMGB1 has not been described as a biomarker for the above-mentioned diseases. However, the current preclinical research results show that HMGB1 antagonists have positive significance in the treatment of Parkinson's disease, stroke, traumatic brain injury, epilepsy, and other diseases. This review discusses the possible mechanisms by which HMGB1 mediates Parkinson's disease, stroke, traumatic brain injury, epilepsy, autism, depression, multiple sclerosis, amyotrophic lateral sclerosis, and the potential of HMGB1 as a biomarker for these diseases. Future research needs to further explore the underlying molecular mechanisms and clinical translation.

show abstract

Section: Introductionmentioning

confidence: 99%

HMGB1 in nervous system diseases: A common biomarker and potential therapeutic target

et al. 2022

View full text Add to dashboard Cite

show abstract

“…45 This is consistent with the reported literature that MPTP induces loss of dopaminergic neurons and then leads to motor dysfunction. 46…”

Section: Discussionmentioning

confidence: 99%

“…45 This is consistent with the reported literature that MPTP induces loss of dopaminergic neurons and then leads to motor dysfunction. 46 It is well known that oxidative stress plays an important role in the initiation or progression of PD. 47 Neuronal tissues are particularly susceptible to oxidative stress compared to any other tissues.…”

Section: Papermentioning

confidence: 99%

The molecular mechanism of three novel peptides from C-phycocyanin alleviates MPTP-induced Parkinson's disease-like pathology in zebrafish

Xu,

Qiu,

Zhang

et al. 2023

Food Funct.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The primary active component of licorice roots and rhizomes (Glycyrrhiza glabra L.) is glycyrrhizin, which is typically used to treat inflammatory illnesses or even as a tonifying herbal remedy. Ren et al reported inhibition of the degeneration of DA neurons, reduction of the count of apoptotic cells in the zebrafish brain, prevention of the loss of their vasculature as well as disordered vasculature, and suppression of the locomotor impairment to exert an anti-PD effect on MPTP-induced PD in zebrafish (Ren et al, 2022).…”

Section: Glycyrrhizinmentioning

confidence: 99%

Natural product-based pharmacological studies for neurological disorders

Puri

Kanojia²,

Sharma³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Central nervous system (CNS) disorders and diseases are expected to rise sharply in the coming years, partly because of the world’s aging population. Medicines for the treatment of the CNS have not been successfully made. Inadequate knowledge about the brain, pharmacokinetic and dynamic errors in preclinical studies, challenges with clinical trial design, complexity and variety of human brain illnesses, and variations in species are some potential scenarios. Neurodegenerative diseases (NDDs) are multifaceted and lack identifiable etiological components, and the drugs developed to treat them did not meet the requirements of those who anticipated treatments. Therefore, there is a great demand for safe and effective natural therapeutic adjuvants. For the treatment of NDDs and other memory-related problems, many herbal and natural items have been used in the Ayurvedic medical system. Anxiety, depression, Parkinson’s, and Alzheimer’s diseases (AD), as well as a plethora of other neuropsychiatric disorders, may benefit from the use of plant and food-derived chemicals that have antidepressant or antiepileptic properties. We have summarized the present level of knowledge about natural products based on topological evidence, bioinformatics analysis, and translational research in this review. We have also highlighted some clinical research or investigation that will help us select natural products for the treatment of neurological conditions. In the present review, we have explored the potential efficacy of phytoconstituents against neurological diseases. Various evidence-based studies and extensive recent investigations have been included, which will help pharmacologists reduce the progression of neuronal disease.

show abstract

Co-treatment with natural HMGB1 inhibitor Glycyrrhizin exerts neuroprotection and reverses Parkinson’s disease like pathology in Zebrafish

Cited by 18 publications

References 88 publications

HMGB1 in nervous system diseases: A common biomarker and potential therapeutic target

HMGB1 in nervous system diseases: A common biomarker and potential therapeutic target

The molecular mechanism of three novel peptides from C-phycocyanin alleviates MPTP-induced Parkinson's disease-like pathology in zebrafish

Natural product-based pharmacological studies for neurological disorders

Contact Info

Product

Resources

About